Phase II study of anlotinib plus durvalumab and chemotherapy as first-line treatment in extensive-stage small cell lung cancer (ES-SCLC): Efficacy and safety analysis.

被引：0
|
作者：
Chen, Lijuan
Zhao, Yanqiu
机构：
[1] Zhengzhou Univ, Dept Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[2] Zhengzhou Univ, Affiliated Canc Hosp, Resp Dept Internal Med, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20131
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety analysis of anlotinib and durvalumab plus chemotherapy in first-line therapy extensive-stage small cell lung cancer (SCLC)
    Chen, L.
    Zhao, Y.
    Wu, H.
    Hu, X.
    Wu, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1580 - S1580
  • [2] Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
    Gao, F.
    Zhao, Y.
    Li, X.
    Li, Y.
    Ma, T.
    Li, Q.
    Tang, X.
    Han, X.
    Yi, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1069 - S1069
  • [3] Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
    Kong, Tiandong
    Chen, Lu
    Zhao, Xiaoli
    Duan, Fangfang
    Zhou, Hanli
    Wang, Lei
    Liu, Danna
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1095 - 1105
  • [4] LUMINANCE: A Phase IIIb Study of Durvalumab plus Platinum-Etoposide for First-Line Treatment of Extensive-Stage SCLC (ES-SCLC)
    Reinmuth, N.
    DeMarinis, F.
    Leighl, N.
    Sadow, S.
    Davey, K.
    Ozguroglu, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S547 - S547
  • [5] Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
    Tiandong Kong
    Lu Chen
    Xiaoli Zhao
    Fangfang Duan
    Hanli Zhou
    Lei Wang
    Danna Liu
    Investigational New Drugs, 2022, 40 : 1095 - 1105
  • [6] UPDATED PFS ANALYSIS OF TORIPALIMAB WITH ANLOTINIB AND CHEMOTHERAPY AS FIRST-LINE THERAPY IN PATIENTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC)
    Luo, Hao
    Jian, Dan
    Feng, Yan
    Zhong, Li
    Chen, Qian
    Guan, Wei
    Zhang, Shiheng
    Luo, Jiamin
    Yang, Xueqin
    Gong, Kan
    Xiong, Yanli
    Li, Mengxia
    Xu, Mingfang
    Pu, Yu
    Zhao, Liang
    Qian, Chengyuan
    Dai, Nan
    Wang, Dong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A490 - A490
  • [7] Anlotinib Combined with Etoposide as Maintenance Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    Shen, B.
    Wu, Y.
    Shi, L.
    Feng, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S509 - S510
  • [8] Anlotinib plus standard chemotherapy as first-line treatment in extensive-stage small cell lung cancer patients
    Zhang, W.
    Yang, H.
    Kong, T.
    Han, B.
    ANNALS OF ONCOLOGY, 2022, 33 : S1580 - S1580
  • [9] Anlotinib Plus Standard Chemotherapy as First-line Treatment in Extensive-Stage Small Cell Lung Cancer Patients
    Zhang, W.
    Yang, H.
    Kong, T.
    Han, B.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S536 - S536
  • [10] Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab
    Daniel, D.
    Kuchava, V.
    Bondarenko, I.
    Ivashchuk, O.
    Spigel, D.
    Dasgupta, A.
    Reddy, S.
    Melkadze, T.
    Jaal, J.
    Kudaba, I.
    Hart, L.
    Matitashvili, A.
    Koynov, K. D.
    Yang, Z.
    Wolfe, S. G.
    Malik, R.
    Morris, S. R.
    Antal, J. M.
    Goldschmidt, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 713 - 713
12345